Bicara Therapeutics
Edit info- Founded: 2020
- Location: Cambridge, MA
- Employee range: 50 - 200
- Clinical stage: Clin1/Clin1b
- Therapy area: Squamous cell carcinoma
- Drug types: ONC
- Lead product: BCA101
- Funding: $108M B Mar 2023; $40M seed Mar 2021
- Investors: Red Tree Venture Capital, RA Capital Management, F-Prime Capital, Eight Roads Ventures, Invus, Piper Heartland Healthcare Capital, Premji Invest, Omega Funds, Bioqube Ventures, Acorn Bioventures, Janus Henderson Investors
bicara.com linkedin.com job board
Business:
Dual-Action Biologics, Antibodies
Drug notes:
Also Clin1 multiple cancers; BCA356 Clin0 solid tumors; undisclosed programs RD solid tumors
About:
Bicara Therapeutics is developing bifunctional antibodies for precision targeted therapies in immuno-oncology. Cancers use various mechanisms to prevent the immune system from their clearance including manipulating the tumor microenvironment. Bicara is using their platform to design bifunctional molecules that precisely target the tumor and deliver a tumor-modulating payload. Besides tumor cell recognition, the second function of the drug is to trap signaling molecules in the tumor microenvironment. By delivering a payload to the tumor, Bicara’s strategy minimizes side effects as lower doses of drug are required for the anti-tumor effect. Bicara’s lead program, BCA101, is in clinical trials for patients with squamous cell carcinoma.
Jobs:
News:
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - StockTitan
googlenews
Sep 16, 2024
Funding-related
external-link
Bicara Therapeutics: Newly Minted Upsized IPO With Positive Early Data (NASDAQ:BCAX) - Seeking Alpha
googlenews
Nov 12, 2024
Funding-related
external-link
Zenas BioPharma, Bicara Therapeutics sets IPO price ranges as summer lull ends - MarketWatch
googlenews
Sep 6, 2024
Funding-related
external-link
Zenas, Bicara set out to raise $180M-plus in separate IPOs to fund autoimmune, cancer prospects - Fierce Biotech
googlenews
Sep 6, 2024
Funding-related
external-link
Two antibody startups file for IPOs amid summer slump - BioPharma Dive
googlenews
Aug 23, 2024
Funding-related
external-link
31,780 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Bought by Walleye Capital LLC - MarketBeat
googlenews
Dec 7, 2024
Funding-related
external-link
Biotech Startups Make Pre-Election Sprint to the Public Markets - The Wall Street Journal
googlenews
Sep 13, 2024
Funding-related
external-link
Bicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year Low - What's Next? - MarketBeat
googlenews
Dec 19, 2024
Science/business updates
external-link
The biggest private biotech investments in December 2023
crunchbase
Jan 11, 2024
Funding-related
external-link
Bicara Therapeutics Announces Publication in Cancer Resea...
crunchbase
Apr 19, 2023
Science/business updates
external-link
Strong Wall Street Debut Shows Potential Of Indian Billionaire-Backed Bicara’s Cancer Drugs - Forbes
googlenews
Sep 21, 2024
Science/business updates
external-link
Bicara Chief Executive Officer Claire Mazumdar will present at the Stifel 2024 Healthcare Conference in New York, NY. View the details and access the live webcasts and replays on our website here: htt
linkedin
Nov 23, 2024
Science/business updates
external-link
Bicara Therapeutics, Adecoagro, and More Stocks See Action From Activist Investors - Barron's
googlenews
Sep 27, 2024
Funding-related
external-link
BCAX IPO News - Oncology biotech Bicara Therapeutics files for a $200 million IPO - Renaissance Capital
googlenews
Aug 22, 2024
Funding-related
external-link
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Down - Time to Sell? - MarketBeat
googlenews
Dec 20, 2024
Science/business updates
external-link
Zenas, MBX, Bicara head to Nasdaq in hot day for biotech ...
fiercebiotech.com
Dec 23, 2024
Funding-related
external-link
Bicara, Zenas seek IPOs to push late-phase assets toward ...
fiercebiotech.com
Dec 23, 2024
Funding-related
external-link
Bicara Therapeutics Expands Management Team with the Appointment of David Raben, M.D., as Chief Medical Officer
crunchbase
Jul 24, 2023
New hires
external-link
Bicara Therapeutics to Participate in Upcoming March Investor Conferences
crunchbase
Mar 5, 2024
Funding-related
external-link
We are excited to share that we have closed our IPO and are listed on Nasdaq as BCAX! This marks an important new chapter for our company as we aim to deliver transformative bifunctional therapies to
linkedin
Sep 23, 2024
Funding-related
external-link
TPG GP A, LLC Acquires New Stake in Bicara Therapeutics Inc - GuruFocus.com
googlenews
Sep 19, 2024
Funding-related
external-link
This cancer drug developer held the Bay State's largest IPO of 2024 - The Business Journals
googlenews
Dec 19, 2024
Funding-related
external-link
Bicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year Low - Should You Sell? - MarketBeat
googlenews
Dec 14, 2024
Science/business updates
external-link
Bicara Therapeutics initiated with bullish view at Morgan Stanley, here's why
crunchbase
Oct 8, 2024
Science/business updates
external-link
Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical and Medical Affairs and Rita Dalal, MBBS, MPH, as VP of Clinical Development - Yahoo Finan
googlenews
Mar 26, 2024
New hires
external-link
Bicara Therapeutics to Host Webinar to Review Latest Clinical Trial Data for BCA101
crunchbase
Sep 8, 2022
Science/business updates
external-link
With IPO, have the capital and resources for clinical studies: Bicara CEO - The Economic Times
googlenews
Sep 26, 2024
Funding-related
external-link
TPG-backed Bicara Therapeutics raises $315 mln in US IPO - Reuters
googlenews
Sep 13, 2024
Funding-related
external-link
At Bicara, we’re driven by a shared vision to bring first-in-class bifunctional therapies to patients with solid tumors. We believe in the power of #diversity and #inclusion, and we’re building a team
linkedin
Dec 9, 2024
New hires
external-link
A Look at an Upcoming IPO in a Quiet Market - Institutional Investor
googlenews
Aug 29, 2024
Funding-related
external-link
Bicara Therapeutics Picks Morgan Stanley For IPO of Up to $150 Million - Bloomberg
googlenews
Jun 28, 2024
Funding-related
external-link
Why Cancer Is The New Cardiology For Hospital Chains
crunchbase
Jul 5, 2023
Science/business updates
external-link
This morning, we announced our third quarter 2024 financial results and business update, highlighting the strong development progress we have made with ficerafusp alfa and the successful completion of
linkedin
Nov 23, 2024
Science/business updates
external-link
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference
crunchbase
Nov 11, 2024
Science/business updates
external-link
🔬 Cancer doesn’t wait. Neither does Bicara Therapeutics.
👩⚕️ $BCAX’s mission as a clinical stage biotherapeutic company is clear: to turn groundbreaking discoveries into real, life-altering new can
linkedin
Oct 23, 2024
Funding-related
external-link
North American Startup Funding Weakened In Q3 As Largest Deal Took Longer To Close
crunchbase
Oct 4, 2024
Funding-related
external-link
Bicara Therapeutics Rings the Opening Bell - Nasdaq
googlenews
Sep 25, 2024
Funding-related
external-link
Cidara Therapeutics Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza
crunchbase
Dec 4, 2024
Science/business updates
external-link
Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity - Yahoo Finance
googlenews
Sep 17, 2024
Funding-related
external-link
Bicara debuts with $40M from Biocon to bankroll ...
fiercebiotech.com
Dec 23, 2024
Funding-related
external-link
Zenas, Bicara set out to raise $180M-plus in separate IPOs
fiercebiotech.com
Dec 23, 2024
Funding-related
external-link
Cantor Fitzgerald starts Bicara Therapeutics with Overweight rating - Investing.com
googlenews
Oct 8, 2024
Science/business updates
external-link
3 Biotechs Seek Over $700M in Renewed IPO Rush - BioSpace
googlenews
Sep 13, 2024
Funding-related
external-link
Bicara Therapeutics initiated with a Not Rated at Goldman Sachs
crunchbase
Nov 20, 2024
Funding-related
external-link
Logo - Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical ...
crunchbase
Mar 29, 2024
New hires
external-link
Billionaire-Backed Cancer Researcher Claire Mazumdar Finds Entrepreneurial Niche
crunchbase
May 25, 2024
Science/business updates
external-link
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 5.8% - Time to Sell? - MarketBeat
googlenews
Dec 18, 2024
Science/business updates
external-link
Bicara raises second $100M+ round of 2023, closing new series C
crunchbase
Dec 12, 2023
Funding-related
external-link
Bicara Therapeutics to Present at Upcoming November Investor Conferences
crunchbase
Nov 8, 2023
Funding-related
external-link
FDA Clears 23andMe BRCA1/2 Consumer Health Risk Report ...
crunchbase
Sep 1, 2023
Science/business updates
external-link
Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical and ...
crunchbase
Apr 17, 2024
New hires
external-link
Indian biopharma spinout raises second nine-figure round this ...
crunchbase
Dec 17, 2023
Funding-related
external-link
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
googlenews
Nov 12, 2024
Science/business updates
external-link
Bicara Therapeutics reports interim data from Phase I/Ib HNSCC treatment trial - Clinical Trials Arena
googlenews
Jun 28, 2024
Science/business updates
external-link
Bicara Therapeutics Announces Closing of $362 Million - GlobeNewswire
googlenews
Sep 16, 2024
Funding-related
external-link
Bicara Therapeutics Announces Oversubscribed $165 Million Series C Financing
crunchbase
Dec 12, 2023
Funding-related
external-link
Bicara Therapeutics files for a $200 million IPO - The Pharma Letter
googlenews
Aug 24, 2024
Funding-related
external-link
Bicara Therapeutics Rings the Nasdaq Stock Market Opening Bell - Nasdaq
googlenews
Sep 25, 2024
Funding-related
external-link
Bicara Therapeutics raises $362 million in Nasdaq debut - The Pharma Letter
googlenews
Sep 17, 2024
Funding-related
external-link
Bicara Therapeutics Reports Strong IPO and Clinical Advancements - TipRanks
googlenews
Nov 13, 2024
Funding-related
external-link
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
web
Dec 23, 2024
Funding-related
external-link
BCAX IPO News - Oncology biotech Bicara Therapeutics sets terms for $200 million IPO - Renaissance Capital
googlenews
Sep 6, 2024
Funding-related
external-link
Bicara and Zenas file for IPOs to push late-phase prospects toward finish line - Fierce Biotech
googlenews
Aug 23, 2024
Funding-related
external-link
At Bicara, we are all working towards the same goal - to transform the lives of people living with #cancer. From the evolution of a small, startup biotech, to where we are now as a public company, it’
linkedin
Dec 20, 2024
Science/business updates
external-link
Stock Market: खबरों वाले ये शेयर करा सकते हैं आज कमाई, बस बनाए रखें नजर
crunchbase
Dec 14, 2023
Funding-related
external-link
We remain steadfast in our mission to transform the treatment of #cancer. With our recent #IPO, we’ve reinforced our commitment to advancing solutions in the fight against this devastating disease. Ou
linkedin
Dec 16, 2024
Funding-related
external-link
Bicara Therapeutics Picks Morgan Stanley For IPO of Up to $150 Million
crunchbase
Jul 1, 2024
Funding-related
external-link
Stocks To Watch: Bicara Therapeutics Sees RS Rating Rise To 83 - Investor's Business Daily
googlenews
Sep 26, 2024
Science/business updates
external-link
3 Biotech IPOs, $703M Raised for Clinical Trials in Cancer, Immunology & Endocrine Disorders - MedCity News
googlenews
Sep 13, 2024
Funding-related
external-link
BCAX IPO News - Oncology biotech Bicara Therapeutics increases shares offered 25% ahead of $250 million IPO - Renaissance Capital
googlenews
Sep 11, 2024
Funding-related
external-link
Bicara Therapeutics aims for up to $828 mln valuation in U.S. IPO - Reuters
googlenews
Sep 6, 2024
Funding-related
external-link
Three’s a crowd? MBX follows Bicara, Zenas into IPO queue - BioCentury
googlenews
Aug 26, 2024
Funding-related
external-link
Bicara Leads Trio of US Biotech IPOs Raising $703 Million - Bloomberg
googlenews
Sep 12, 2024
Funding-related
external-link
Oncology biotech Bicara unveils IPO pitch same day as Zenas - Endpoints News
googlenews
Aug 23, 2024
Funding-related
external-link
Bicara Therapeutics Appoints Mike Powell, Ph.D., and Christopher Bowden, M.D. to Board - citybiz
googlenews
Aug 15, 2024
New hires
external-link
763,943 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Bought by Wellington Management Group LLP - MarketBeat
googlenews
Dec 14, 2024
Funding-related
external-link
Bicara Therapeutics Appoints Lara Meisner as Chief Legal Officer
crunchbase
Dec 18, 2023
New hires
external-link
Bicara Therapeutics picks Morgan Stanley for IPO of up to $150m.
crunchbase
Jul 1, 2024
Funding-related
external-link
Targeted cancer therapy player Bicara Therapeutics raises $165 mn in Series C financing
crunchbase
Dec 13, 2023
Funding-related
external-link
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference - GlobeNewswire
googlenews
Nov 11, 2024
Science/business updates
external-link
An exciting moment for our team today as we celebrated becoming a public company by ringing the #OpeningBell at Nasdaq! This moment marks an important new chapter in our journey, reinforcing our commi
linkedin
Oct 23, 2024
Funding-related
external-link
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference
web
Dec 23, 2024
Science/business updates
external-link
Biocon accused of committing IP theft to create cancer biotech Bicara - Fierce Biotech
googlenews
Oct 24, 2024
Science/business updates
external-link
BCAX IPO News - Oncology biotech Bicara Therapeutics prices upsized IPO at $18, the high end of the range - Renaissance Capital
googlenews
Sep 13, 2024
Funding-related
external-link
Zenas, MBX and Bicara all head to Nasdaq in hot day for biotech IPOs - Fierce Biotech
googlenews
Sep 13, 2024
Funding-related
external-link
Bicara Therapeutics Expands Board of Directors with Appointments of Mike Powell, Ph.D., and Christopher Bowden, M.D. - Yahoo Finance
googlenews
Aug 15, 2024
New hires
external-link
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
web
Dec 23, 2024
Science/business updates
external-link
Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering - GlobeNewswire
googlenews
Sep 12, 2024
Funding-related
external-link
Year in photos: Makers, musicians, faces and places of 2024
crunchbase
Dec 20, 2024
Science/business updates
external-link
Bicara Therapeutics initiated with a Buy at H.C. Wainwright
crunchbase
Dec 6, 2024
Science/business updates
external-link
Bicara Therapeutics Reports Updated Interim Phase 1/1b Data of Ficerafusp Alfa (BCA101) in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) - Business Wire
googlenews
Jun 27, 2024
Science/business updates
external-link
Amgen Highlights Positive Phase III Lumakras Data in ...
crunchbase
Aug 4, 2023
Science/business updates
external-link
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com